SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Cerecor is a biotechnology business based in the US. Cerecor shares (CERC) are listed on the NASDAQ and all prices are listed in US Dollars. Cerecor employs 30 staff and has a trailing 12-month revenue of around $6.4 million.
SoFi Invest
tastyworks
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $2.88 |
200-day moving average | $3.01 |
Wall St. target price | $6.50 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.87 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $N/A from 2021-11-26
1 week (2023-01-17) | N/A |
---|---|
1 month (2022-12-24) | N/A |
3 months (2022-10-24) | N/A |
6 months (2022-07-24) | N/A |
1 year (2022-01-24) | N/A |
---|---|
2 years (2021-01-28) | -100.00% |
3 years (2020-01-28) | -100.00% |
5 years (2018-01-26) | -100.00% |
Revenue TTM | $6.4 million |
---|---|
Gross profit TTM | $-18,536,584 |
Return on assets TTM | -72.52% |
Return on equity TTM | -213.81% |
Profit margin | 0% |
Book value | $0.23 |
Market capitalisation | $285 million |
TTM: trailing 12 months
We're not expecting Cerecor to pay a dividend over the next 12 months.
Over the last 12 months, Cerecor's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerecor's is 1.4406. This would suggest that Cerecor's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cerecor Inc. , a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.